Evaluation of physical rehabilitation in patients receiving curative treatment for head and neck cancer: The NUTRIMOUV randomized phase II trial Authors: Marie Vinches, Chloé Janiszewski, Simon Thezenas, Delphine Delample, Pierre Boisselier, Stéphane Jacquot, Pierre Senesse, Kerstin Faravel Published: 2025 ABSTRACT AbstractPurposePatients with head and neck squamous cell carcinoma (HNSCC) undergoing curative radiotherapy or chemoradiotherapy often experience adverse effects affecting physical and psychosocial health, which can lead to a deconditioning cycle, worsening side effects, treatment tolerance and quality of life. This multicenter phase II study evaluated whether physical rehabilitation combined with nutritional care could improve exercise tolerance and reverse the deconditioning cycle.MethodsPatients with localized HNSCC undergoing curative radiotherapy or chemoradiotherapy were randomized into two groups. One group engaged in a physical rehabilitation (PR) program, including quadriceps electrical stimulation three times a week during treatment, followed by three weekly sessions of home-based ergocycle training for 12 weeks, while the control (CT) group received standard care. Both groups received nutritional care. Success of the PR program was defined as a 40% increase in the patient’s baseline endurance time or the ability of the patient to sustain the activity for 30 min at three months.ResultsSeventy patients were included, with 33 patients in the PR group. The success rate was higher in the PR group program (68%, CI 95% 48–84) than to the CT group (27%, CI 95% 16–48). From T0 to T2, the median endurance time changed by + 54% in PR vs. -55% in CT. No significant difference was observed regarding quality of life.ConclusionsOur results highlight that physical rehabilitation combined with nutritional care is feasible in this setting, and could improve exercise tolerance without modifying patient’s quality of life. It emphasizes the crucial role of physical activity during cancer treatment.Clinical trial registration number.NCT02135185 on February 6, 2014 (retrospectively registered).Keywords: Head and neck cancers, Physical activity, Rehabilitation, Dietary counseling, Chemoradiotherapy Introduction Head and neck cancers (HNCs) account for approximately 10% of cancers in France and are the seventh most frequent cancer worldwide [1]. Head and neck squamous cell carcinoma (HNSCC) is the most common HNC. Its incidence is strongly associated with tobacco and alcohol consumption, and with poor dietary and physical behaviors that do not align with the World Cancer Research Fund recommendations [2, 3]. The prognosis for patients with HNSCC is largely determined by the cancer stage at diagnosis, with a 5-year overall survival rate ranging between 55 and 65% [4]. While the incidence of human papillomavirus (HPV)-associated oropharyngeal cancers is rapidly increasing, these cancers have a very favorable prognosis, with a 5-year overall survival rate of 96.9% for stage I cancer [5]. Thus, it is essential to incorporate supportive care to improve survivors’ quality of life (QoL) following treatment. Radiotherapy represents one of the cornerstones of treatment for early-stage and locally advanced HNSCC. It can be used either as a standalone modality or in combination with systemic treatments such as platinum-based chemotherapy or epithelial growth factor receptor-targeted therapy (e.g., cetuximab), either as a curative modality or as an adjuvant treatment following surgery. Side effects of radiotherapy (RT), with or without concomitant chemoradiotherapy (CRT), usually include difficulties in eating, swallowing and speech, which can affect physical and psychosocial aspects of patients’ QoL. Consequently, patients may enter a vicious deconditioning cycle that exposes them to greater side effects. Sedentary behavior is an additional risk factor for cancer treatment that can increase treatments’ side effects and the overall mortality [6]. Physical deconditioning can increase fatigue and decrease exercise tolerance, affecting patients’ QoL. In other settings, physical activity has been shown to reduce fatigue, improve mood, and increase QoL [7, 8]. For example, Courneya et al. demonstrated the benefits of physical activity on self-esteem, body composition and physical fitness of patients with breast cancer [9]. Previous studies have used electrostimulation and ergocycle exercises to introduce physical activity in this heavily treated population [10, 11]. In this multicenter randomized phase II trial, we evaluated whether physical rehabilitation combined with nutritional support could improve exercise tolerance and reverse the deconditioning cycle in patients with HNSCC. Material and methods Population Patients aged between 18 and 75 years of age, with histologically confirmed non-metastatic HNSCC and scheduled to receive curative RT or CRT for at least 6 weeks were included in the study. Other inclusion criteria included a Karnofsky performance status ≥ 60%. Eligible patients were screened with a cardiopulmonary exercise test to detect any contraindications to physical activity. The main exclusion criteria were nasopharyngeal tumors, patient undergoing neoadjuvant chemotherapy, parenteral nutrition, medical contraindication to physical activity (e.g., pulmonary arterial hypertension, uncontrolled heart failure, and recent myocardial infarction), and exercise-induced desaturation. Study design Patients with non-metastatic HNSCC were randomly (1:1 ratio) assigned to either the physical rehabilitation (PR) group or the control (CT) group. Both groups received standardized dietary counseling. PR group had three sessions per week of quadriceps electrostimulation (ES) during the radiotherapy period followed by three sessions per week of home-based ergocycle exercise session during 12 weeks. The patients in the CT group did not receive any physical activity intervention until study completion. The study schedule is detailed in Fig. 1. Study schedule. R: Randomization, PR: Physical Rehabilitation, CT: Control; RT: radiotherapy, CRT: chemoradiotherapy, T0: baseline, T1: last day of radiotherapy, T2: 3 months after completion of RT or CRT, HR-QoL: EORTC QLQ-C30 and MOS SF-36 questionnaires The TenAlea® Software was used for patient randomization, and stratification was performed according to center, concomitant chemotherapy (yes vs. no) and malnutrition status (yes (weight loss ≥ 5% in 1 month or weight loss ≥ 10% in 6 months) vs. no) [12, 13]. The primary endpoint was success rate, defined as the proportion of patients who reached 30 min in the endurance test or increased their endurance by ≥ 40% at 3 months. Secondary endpoints were QoL, precariousness, general health perception, performance status, daily physical activity, addiction to tobacco and alcohol and feasibility. The study was designed and sponsored by the Montpellier Cancer Institute, France. Data collection was carried out by investigators at each participating center. The biometric unit of Montpellier Cancer Institute performed the statistical analyses. Treatment Dietary counseling All patients included in the study underwent eight individual face-to-face sessions of dietary education performed by a dietician. The initial session was performed before patient’s inclusion, while subsequent sessions were held weekly throughout patient’s treatment. Each session included a nutritional status assessment (according to criteria defined by the French National Authority for Health [13]) and nutrition care tailored to the patient’s caloric requirements. Nutrition advice was customized to address potential treatment-related toxicities and to provide therapeutic nutritional education. For patients who were not malnourished, the objective was to achieve weight stabilization, and the diet program was based on diet advice. For malnourished patients who experienced a weight loss of ≥ 5% over the past month or ≥ 10% over the past six months, a nutritional care plan was recommended and included enteral nutrition through oral supplements or tube feeding. The objective was to achieve an energy intake of 30–35 kcal/kg body weight and 1.2–1.5 g protein/kg per day. Additional educational sessions could be done at patient’s request or if deemed necessary by the investigators. Physical rehabilitation program Prior to inclusion, patient’s maximum work capacity (Wmax) was determined by cardiopulmonary exercise testing (CPET) [14]. Patients in the PR group followed a 19-week physical activity intervention including: 1) Individual and supervised neuromuscular electrostimulation sessions (55 min each, using Compex Cefar®), at the hospital, three times a week during patients’ RT or CRT (7 weeks). 2) Three home-based ergocycle exercise sessions per week, including one supervised session, during 12 weeks following the completion of RT or CRT. The target was to achieve a total of 150 min of sustained intensity exercise per week [15]. Heart rate was monitored during all the exercise sessions using a Polar watch®, Polar Electro France (Polar), Biarritz, France. Outcome measures Baseline patient characteristics including age, sex, medical history, performance status, weight, and alcohol and tobacco consumption were recorded. Oral intake was assessed at baseline (T0), on the last day of radiotherapy (T1), and 3 months after completion of radiotherapy (T2), using a verbal analogue scale (VAS) of food ingesta. The efficacy of the PR program was assessed through an endurance test at T0, T1, and T2. This test consisted in cycling at 70% of the Wmax determined during the CPET, using a mechanically braked calibrated cycloergometer (DKN Technology, AM-3i model). After three minutes of unloaded pedaling, the power output was raised to 70% of the Wmax. Patients then cycled at this constant submaximal workload until experiencing exhaustion. The primary outcome measured was the duration of the cycling session until exhaustion, with a maximum duration of 30 min. A significant increase in endurance was defined as either a 40% improvement in the patient’s baseline endurance time at T2 or the ability to sustain the activity for a duration of 30 min. Patient precariousness was assessed at baseline using the "Evaluation de la Précarité et des Inégalités de santé dans les Centres d’Examens de Santé (EPICES)" score (French scale to assess precariousness and health inequalities in health care centers), which is based on individual conditions of deprivation [16]. The EORTC QLQ-C30 and MOS SF-36 questionnaires were used to assess health related quality of life at T0, T1 and T2. The feasibility of the program was assessed by evaluating the adherence to the training sessions (measured as the percentage of exercise duration per week compared to the maximum theoretical exercise duration) and adverse events reported by patients in the PR group. Statistical considerations The primary endpoint was success rate, defined as the proportion of patients who reached 30 min in the endurance test or increased their endurance by ≥ 40% at 3 months. Assuming a significant endurance increase in 45% of patients of the CT group and in 70% of the PR group, including 70 patients, with 35 patients in each treatment arm, would provide the study with a power of 90% to detect a difference at a two-sided, with 5% significance level. Quantitative data were reported as median and range and compared using the Kruskall-Wallis test. Qualitative data were reported as percentages and frequencies and compared using Chi-squared test. Randomization (1:1) was stratified by center (4), chemotherapy status (yes vs. no) and malnutrition status (yes vs. no). The efficacy analyses were conducted in the intention-to-treat population. All statistical tests were two-sided, with an alpha level of 5% considered to indicate statistical significance. STATA 11 [Stata Corporation, College Station, Tx USA] was used to perform the analysis. Results Patient population Between July 2012 and November 2015, 115 patients were screened and 70 patients were enrolled at four French centers. After inclusion, 33 patients were randomized in the PR group and 37 patients in the CT group (Fig. 2). The two treatment groups were well balanced with respect to the patients’ baseline characteristics (Table 1). The median age was 61.5 years (range 39–76) and 84% of patients were male. According to the EPICES score, 33% of included patients were precarious (i.e. score > 30) [16]. Study flowchart Table 1Patients’ baseline characteristicsCT (n = 37)PR (n = 33)Total (n = 70)Age (years), mean (SD)62.1 (7.1)58.4 (9.1)60.3 (8.3)Male, n (%)29 (78.4)30 (90.9)59 (84.3)Malnourished patients*, n (%)7 (18.9)3 (9.1)10 (14.3)Precariousness**, n (%)13 (39.4)8 (26.7)21 (33.3)HPV status Positive17 (45.9)12 (36.4)29 (41.4) Negative13 (35.1)10 (30.3)23 (32.9) Unknown7 (18.9)11 (33.3)18 (25.7)Karnofsky PS, mean (SD)92.2 (8.2)94.5 (6.2)93.3 (7.4)Alcohol consumption Yes, n (%)17 (45.9)7 (21.2)24 (34.3) Former drinker, n (%)8 (21.6)16 (48.5)24 (34.3)Tabacco consumption Yes10 (27.0)4 (12.1)14 (20.0) Former smoker23 (62.2)26 (78.8)49 (70.0)Pack per year, median (range)45.0 (5: 94)31.0 (2: 117)40.0 (2: 117)Tumor location, n (%) Oropharynx21 (56.8)16 (48.5)37 (52.9) Oral cavity12 (32.4)11 (33.3)23 (32.9) Occult primary—Cervical node10 (27)12 (36.4)22 (31.4) Hypopharynx1 (2.7)4 (12.1)5 (7.1) Larynx3 (8.1)1 (3.0)4 (5.7) Other1 (2.7)1 (3.0)2 (2.9)Postoperative treatment16 (43.2)22 (66.7)38 (54.3)Treatment planned, n (%) RT11 (29.7)10 (30.3)21 (30.0) CRT26 (70.3)23 (69.7)49 (70.0)*weight loss ≥ 5% during the last month or ≥ 10% during the last 6 months**using the "Evaluation de la Précarité et des Inégalités de santé dans les Centres d’Examens de Santé (EPICES)" score (French scale to assess precariousness and health inequalities in health care centers)CT control group, PR physical rehabilitation group, PS performance status, HPV human papillomavirus, RT radiotherapy, CRT chemoradiotherapy Patients’ baseline characteristics *weight loss ≥ 5% during the last month or ≥ 10% during the last 6 months **using the "Evaluation de la Précarité et des Inégalités de santé dans les Centres d’Examens de Santé (EPICES)" score (French scale to assess precariousness and health inequalities in health care centers) CT control group, PR physical rehabilitation group, PS performance status, HPV human papillomavirus, RT radiotherapy, CRT chemoradiotherapy Oncological treatment All patients underwent radiotherapy with a median duration of 50 days (range 30–83), and the median delivered dose was 70 Gy (range 44–70). Seventy percent of patients (49/70) also received concomitant chemotherapy. Of these, forty-four patients received platinum-based regimen, while four patients were treated with cetuximab. Dietary counseling The results related to dietary counseling are summarized in Table 2. On average, patients attended a median of 8 dietary counseling sessions (range 6–12). Nutritional adaptation was introduced during the first session for 78.3% of patients (n = 54). A total of 87% of patients (n = 60) received counseling on dietary enrichment, while 81.2% (n = 56) were advised to use oral nutritional supplements. Additionally, 47.1% of patients (n = 33) required artificial nutrition at some point during treatment. Among these, 81.8% (n = 27) received enteral nutrition, 15.2% (n = 5) received parenteral nutrition, and 3% (n = 1) received both forms of nutrition. The median duration of artificial nutrition was 8.1 weeks (range 0.3–21.9). Notably, 7.1% of patients (n = 5) had already started artificial nutrition prior to treatment, and 40% of patients (n = 28) were still receiving it at the end of the treatment. Most patients experienced weight loss during the study (80%, n = 56), with a median weight change of −6.9% (range −22.3- + 11.8%) from baseline to T2. Table 2Dietary counselingCT (n = 37)PR (n = 33)Total (n = 70)Number of visits, median (range)8 (6–12)8 (6–12)8 (6–12)Missing101Oral nutritional supplementationNo7 (19.4)6 (18.2)13 (18.8)Yes29 (80.6)27 (81.8)56 (81.2)Artificial nutritionParenteral2 (13.3)3 (16.7)5 (15.2)Enteral *13 (86.7)14 (77.8)27 (81.8)Both0 (0.0)1 (5.6)1 (3.0)Duration of artificial nutrition (week)Median (range)10.6 (0.9—21.9)7.9 (0.3–21.3)8.1 (0.3–21.9)Missing426CT control group, PR physical rehabilitation group*Excluding oral nutritional supplement Dietary counseling CT control group, PR physical rehabilitation group *Excluding oral nutritional supplement Physical rehabilitation and quality of life All patients were treated according to their allocated group and 16 patients were not evaluable for efficacy due to missing data. The median adherence rate was 87% (range 19–117) for ES sessions and 45% (range 0–186) for ergocycle exercise sessions. Four patients performed more electrostimulation sessions than prescribed. In the post-treatment period, two patients exceeded the recommended number of ergocycling sessions, while five patients did not perform any home-based ergocycle exercise sessions. The median follow-up duration was 4.96 months (95% CI: 4.8–5.2) for all 70 patients. No significant difference in endurance was observed between the two groups at T1 following the supervised neuromuscular electrostimulation sessions. The success rate in the PR group was 68% (CI 95% [48–84], n = 19/54) compared to 27% in the CT group (CI 95% [16–48], n = 7/54). At T0, the median endurance time was 8 min (range 1.5–30) in the CT group and 10.1 min (range 1–30) in PR group. At T2, the median endurance times were 3.6 min (range 0–30) and 15.5 min (range 0.3–30) in the CT and PR groups, respectively (Fig. 3). The median change in endurance time from T0 to T2 was + 54% in the PR group vs. −55% in the CT group. Median endurance time. CT control, PR physical rehabilitation, T0 baseline, T1 last day of radiotherapy, T2 3 months post-radiotherapy There was no difference regarding QoL between the PR group and the CT group. Discussion Our study indicates that a physical rehabilitation protocol, integrating a nutritional approach with artificial nutrition, is feasible both during and after oncological treatment in patients with non-metastatic HNSCC. We designed a PR program that incorporated electrostimulation during radiotherapy, followed by active home-based training using an ergocycle. Overall, the PR program improved exercise tolerance without modifying patients’ QoL. It seems that the efficacy of the PR program was mainly associated with home-based exercises, despite a compliance rate of 45%. Toth et al. reported that electrostimulation in patients with breast cancer undergoing chemotherapy had minimal impact on fiber contractility and led to a reduction in subsarcolemmal mitochondria during cancer treatment [17]. However, electrostimulation may still be considered a complementary approach for muscle strengthening in patients with limited mobility [18, 19]. A prehabilitation program combining head and neck physiotherapy (i.e., trismus prevention, swallowing and mastication), with physical activity, nutrition and other supportive care interventions has not yet been clearly defined in the current guidelines [20–22]. In our study population, 54,3% of patients were treated in a postoperative setting, and could have benefited from earlier prehabilitation [23]. To optimize patients’ physical status and QoL during and after treatment, we believe that early supportive care, integrating nutrition and rehabilitation programs, should be initiated as soon as possible, ideally before treatment begins. Recently, we have witnessed the development of early supportive care intervention programs. The first studies were performed in the palliative care setting, but an increasing number of randomized trials are being developed to evaluate interdisciplinary nutrition and rehabilitation programs to anticipate the side effects of cancer treatments [24]. National recommendations define nutrition programs according to the nutritional status of patients and their oncological treatment. Nutritional interventions, like medication, require specialized care management and patient consent but not the direct and active implication of the patient. Nutrition is administered either orally or via tube feeding, with the only intervention being the connection or disconnection of the enteral feeding. In contrast, adapted physical activity requires active patient involvement. During concurrent chemoradiotherapy, acute side effects such as fatigue, nausea, vomiting, and pain secondary to mucositis are particularly intense and prolonged. For example, the use of tube feeding during CRT for tumors in the oral cavity or oropharynx, which accounted for 86% of our study population, is used in approximately 80% of patients [25]. Fatigue is a common side effect of CRT, affecting at least 60% of patients with HNC [26]. However, few studies have investigated the optimal timing for physical rehabilitation in this population. The burden of cancer treatment often hinders the implementation of a concomitant physical activity program. The time of cancer diagnosis may represent a suitable opportunity for patients to consider lifestyle changes [27]. During this critical period, patients’ motivation to quit tobacco or alcohol consumption, or to begin physical activity, is increased [28]. This could be an ideal time to raise awareness of the importance of physical activity for improving health-related QoL, accelerating recovery from treatment side effects, and preventing other health issues. The main limitations observed were those related to acceptance and adherence to the PR program. Furthermore, adherence may be even lower in the head and neck cancer population, where a high proportion of patients are precarious, as was the case for one-third of our study population. Nevertheless, previous studies have shown that initiating a physical activity program at the end of cancer treatment does not impact muscle mass but may increase patient adherence to the program in this population [29]. To enhance patients’ adherence and program effectiveness, we suggest informing patients about physical activity recommendations before and during cancer treatment, and begin a supervised program only after the completion of radiotherapy and management of acute side effects. Behavior change can be complex, particularly during cancer treatment, underscoring the importance of initiating supportive interventions before treatment begins. Our experience suggests that integrating a theory-based patient education component, such as implementation intentions theory, into interventional protocols increases the likelihood that patients will adopt new behaviors [30, 31]. Moreover, patient behavior change is more likely to be successful when it is carefully planned. A recent study patient education is an essential component to increase participation in interventions [32]. One key objective of patient education programs is to empower patients, enabling them to engage actively in their treatment. While the use of the ergocycle facilitated standardization in a trial setting, it may limit patient motivation. Offering patients choices regarding the type of physical activity (e.g. walking or cycling), combining different activities, and deciding where (e.g. outdoors or indoors) and how (e.g. alone or in groups) to exercise could enhance adherence. Finally, incorporating patient partners into healthcare teams would likely enhance patient adherence and provide social benefits [33]. Our study showed that combining physical rehabilitation with nutritional care is feasible in this setting and highlighted the importance of physical activity during cancer treatment. The PR program improved exercise tolerance without affecting patients’ QoL. However, adherence and program effectiveness could be further improved by taking into account the burden of the cancer treatment. Providing structured information before and during treatment, along with initiating a supervised physical activity program after treatment completion may be a better strategy. Acknowledgements The authors would like to thank all the patients who participated in the study, as well as the participating centers for their interest, collaboration, and active involvement. Special thanks are extended to the medical staff of all recruitment centers, particularly the nutritionists. The authors also express their gratitude to Dr. Jean-Marc Levecq and Dr. Antoine Serre for their support during this investigation. Additionally, they thank Dr. Fanny Salasc of the Montpellier Cancer Institute (ICM, Montpellier, France) for her medical writing and editorial assistance. Author contributions PS, DD, CJ, PB and SJ have taken part in the planning and reporting of the work described in the article. ST and PS conducted the data extraction. MV, KF and PS conducted the data review and validation. All authors contributed to the manuscript, have reviewed and agreed upon the manuscript content. Funding This work was funded by the French Ministry of Health (Institut National Du Cancer), 2010-229. Data Availability No datasets were generated or analysed during the current study. Declarations Ethic approval The trial protocol was approved by a local ethics committee (Comité de Protection des personnes Sud Méditerranée III, reference 2011.11.03) and by the authorities (ClinicalTrials.gov number, NCT02135185, ID RCB: 2011-A01289-32). The trial was conducted in accordance with the Declaration of Helsinki. Consent to participate All patients provided oral and written informed consent. Competing interests The authors declare no competing interests. Footnotes Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Contributor Information Pierre Senesse, Email: pierre.senesse@icm.unicancer.fr. Kerstin Faravel, Email: kerstin.faravel@icm.unicancer.fr. References Associated Data Data Availability Statement No datasets were generated or analysed during the current study.